| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/22/2001 | CA2380775A1 Benzoic acid derivatives and their use as ppar receptor agonists |
| 02/22/2001 | CA2380753A1 Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor |
| 02/22/2001 | CA2380653A1 Mycophenolate mofetil in association with peg-ifn-.alpha. |
| 02/22/2001 | CA2380642A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | CA2380635A1 Tgf-.alpha. polypeptides, functional fragments and methods of use therefor |
| 02/22/2001 | CA2379356A1 Novel hypoxanthine and thiohypoxanthine compounds |
| 02/22/2001 | CA2379168A1 Chimeric dna/rna ribozymes containing propanediol |
| 02/22/2001 | CA2378332A1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | CA2377646A1 Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 02/22/2001 | CA2377637A1 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands |
| 02/21/2001 | EP1077218A2 Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors |
| 02/21/2001 | EP1076711A2 Human apoptosis associated proteins |
| 02/21/2001 | EP1076699A2 Method of inhibiting osteoclast activity |
| 02/21/2001 | EP1076698A2 Transgenic plant-derived human blood coagulation factors |
| 02/21/2001 | EP1076696A2 Human receptor molecules |
| 02/21/2001 | EP1076691A1 Cellular and animal models for diseases associated with altered mitochondrial function |
| 02/21/2001 | EP1076665A1 Oral administration of immunoglobulins for treating autoimmune hearing loss |
| 02/21/2001 | EP1076663A1 Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors |
| 02/21/2001 | EP1076658A1 Serotonergic agents |
| 02/21/2001 | EP1076651A1 Substituted sulphonyl cyanamides, method for producing same and their use as medicament |
| 02/21/2001 | EP1076650A1 Aryl fused azapolycyclic compounds |
| 02/21/2001 | EP1076647A2 Antipsychotic indolyl derivatives |
| 02/21/2001 | EP1076644A1 N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
| 02/21/2001 | EP1076643A1 Biphenyl derivatives |
| 02/21/2001 | EP1076641A1 Inhibitors of impdh enzyme |
| 02/21/2001 | EP1076569A1 Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| 02/21/2001 | EP1076563A1 Dipeptide caspase inhibitors and the use thereof |
| 02/21/2001 | EP1076562A1 Glucocorticoid receptor antagonists for the treatment of dementia |
| 02/21/2001 | EP1076561A2 Combination therapy for the treatment of tumors |
| 02/21/2001 | EP1076560A1 Inhibition of protein kinases with piridinylimidazoles |
| 02/21/2001 | EP1076559A2 Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease |
| 02/21/2001 | EP1076557A1 Ccr-3 receptor antagonists |
| 02/21/2001 | EP1076553A2 Pharmaceutical, hygienic and/or cosmetic compositions containing sea water and uses |
| 02/21/2001 | EP0975609A4 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent |
| 02/21/2001 | EP0527852B2 Method and compositions for treating injury |
| 02/21/2001 | CN1284994A Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria |
| 02/21/2001 | CN1284958A Metallocorrinoids as biologically compatible carriers of pharmocological agents |
| 02/21/2001 | CN1284957A Imidazonaphthyridines and their use in inducing cytokine biosynthesis |
| 02/21/2001 | CN1284952A Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
| 02/21/2001 | CN1284950A Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists |
| 02/21/2001 | CN1284948A Indezole bioisostere replacement of catechol in therafeutically active compounds |
| 02/21/2001 | CN1284947A Carboxyl acid substituted heterocycles as metalloproteinase inhibitors |
| 02/21/2001 | CN1284945A Substituted pyriding and pyridazine compounds and their pharmaceutical use |
| 02/21/2001 | CN1284944A Integrin receptor antagonists |
| 02/21/2001 | CN1284942A Matrix metalloprotease inhibitors |
| 02/21/2001 | CN1284883A Method to enhance an immune response of nucleic acid vaccination |
| 02/21/2001 | CN1284870A Utilization of alkyl hydrogen fumerates for treating psoriasis, psoriatic arthritis, neurodermatitis and regional enteritis |
| 02/21/2001 | CN1284861A Novel pharmaceutical compositions of uridine triphosphate |
| 02/21/2001 | CN1284505A Azabicyclic compound |
| 02/21/2001 | CN1284379A Production process of salt algae powder and preparation of salt algae powder capsule |
| 02/21/2001 | CN1284349A Medicine pill for preventing and treating pathological seaility |
| 02/21/2001 | CN1062180C Medicine for tonifying the kidney and strengthening Yang |
| 02/21/2001 | CN1062166C Chinese drugs preparation for promoting child intelligence development and preparation method of its solvable granules |
| 02/21/2001 | CN1062137C Placenta Tonic and its processing method |
| 02/20/2001 | US6191261 Immunoglobulin that preferential binds a growth factor; for the diagnosis and treatment of cell proliferative defects; antiproliferative agents |
| 02/20/2001 | US6191172 Used in drugs and cosmetics |
| 02/20/2001 | US6191161 Prolylendopeptidase inhibitors |
| 02/20/2001 | US6191159 Anticoagulants |
| 02/20/2001 | US6191149 Heterocyclic derivative and medicine |
| 02/20/2001 | US6191147 Pyrazole compounds and uses thereof |
| 02/20/2001 | US6191139 Antidepressant |
| 02/20/2001 | US6191130 Cyclohexane derivatives difunctionalised in 1,4 as ligands of 5T H1A receptors |
| 02/20/2001 | US6191127 Antiinflammatory agents, autoimmune diseases, cardiovascular disorders, nervous system disorders |
| 02/20/2001 | US6191123 Organic-arsenic compounds |
| 02/20/2001 | US6190909 TH2-specific gene |
| 02/20/2001 | US6190897 Nucleotide sequence coding hydrolase; for use in digestion of animal feeds |
| 02/20/2001 | US6190887 Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein |
| 02/20/2001 | US6190880 Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| 02/20/2001 | US6190875 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 02/20/2001 | US6190693 Administering pharmaceutical formulation comprising hormonal replacememt for treating or preventing menopausal condition and folic acid |
| 02/20/2001 | CA2223624C Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines |
| 02/20/2001 | CA2192289C Substituted heterocyclic derivatives |
| 02/20/2001 | CA2158991C Adipocyte differentiation inhibiting peptide and adipocyte differentiation inhibiting agent using the peptide as active component thereof |
| 02/20/2001 | CA2116617C Novel esculetin derivatives and pharmaceutical composition |
| 02/20/2001 | CA2060208C Wound healing |
| 02/20/2001 | CA1341182C Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof |
| 02/15/2001 | WO2001011054A1 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STAPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB) |
| 02/15/2001 | WO2001011050A1 Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY |
| 02/15/2001 | WO2001011041A1 MONOMERIC PROTEIN OF THE TGF-β FAMILY |
| 02/15/2001 | WO2001011024A2 Bryostatins, bryopyrans and polyketides: compositions and methods |
| 02/15/2001 | WO2001011023A1 Treatment of inflammatory or malignant disease using dnazymes |
| 02/15/2001 | WO2001010906A1 Crystallization and structure determination of staphylococcus aureus elongation factor p |
| 02/15/2001 | WO2001010903A2 Proteases and protease inhibitors |
| 02/15/2001 | WO2001010895A1 Streptogramin derivatives, production thereof and compositions containing the same |
| 02/15/2001 | WO2001010894A2 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 02/15/2001 | WO2001010867A1 Vitronectin receptor antagonists useful for the treatment of strokes |
| 02/15/2001 | WO2001010866A1 Interleukin-5 inhibiting 6-azauracil derivatives |
| 02/15/2001 | WO2001010865A1 p38MAP KINASE INHIBITORS |
| 02/15/2001 | WO2001010847A2 Novel integrin receptor antagonists |
| 02/15/2001 | WO2001010846A2 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system |
| 02/15/2001 | WO2001010842A2 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 02/15/2001 | WO2001010834A2 Antibacterial agents |
| 02/15/2001 | WO2001010833A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 02/15/2001 | WO2001010827A1 Arylsulfonamido-substituted hydroxamic acid derivatives |
| 02/15/2001 | WO2001010823A1 Carboxylic acid amides, their production and their use as drugs |
| 02/15/2001 | WO2001010741A1 Valve with a two-component seal |
| 02/15/2001 | WO2001010468A2 Drug-carrier complexes and methods of use thereof |
| 02/15/2001 | WO2001010457A2 Pharmaceutical compositions containing tripeptides |
| 02/15/2001 | WO2001010455A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 02/15/2001 | WO2001010444A2 A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate |